These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 29974277

  • 1. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, Okada AA, Iida T, Sekiryu T.
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH, Kim CG, Lee DW, Yoo SJ, Lew YJ, Cho HJ, Kim JY, Lee SH, Kim JW.
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 4. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM, Ouchi C, Shiode Y, Kimura S, Matoba R, Morita T, Morizane Y.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3099-3107. PubMed ID: 38625447
    [Abstract] [Full Text] [Related]

  • 5. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 6. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC, Lee DK, Kim SH, You YS, Kwon OW.
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [Abstract] [Full Text] [Related]

  • 7. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

  • 8. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K, Kaneko H, Kataoka K, Ueno S, Chang-Hua P, Ito Y, Terasaki H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [Abstract] [Full Text] [Related]

  • 9. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y, Sugiyama A, Tanabe N, Kikushima W, Kume A, Iijima H.
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M, Kano M, Itagaki K, Sekiryu T.
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [Abstract] [Full Text] [Related]

  • 11. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V, Upaphong P, Patikulsila D, Jirarattanasopa P, Choovuthayakorn J, Watanachai N, Kunavisarut P, Ratanasukon M, Bhurayanontachai P, Ingviya T, Bressler SB, Bressler NM.
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [Abstract] [Full Text] [Related]

  • 12. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.
    BMC Ophthalmol; 2016 Jul 27; 16():127. PubMed ID: 27465105
    [Abstract] [Full Text] [Related]

  • 13. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 27; 255(3):541-548. PubMed ID: 27687988
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H.
    Jpn J Ophthalmol; 2018 Mar 27; 62(2):144-150. PubMed ID: 29411171
    [Abstract] [Full Text] [Related]

  • 15. Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kang EC, Choi S, Koh HJ.
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov 27; 255(11):2157-2163. PubMed ID: 28819823
    [Abstract] [Full Text] [Related]

  • 16. RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION.
    Wakazono T, Yamashiro K, Oishi A, Ooto S, Tamura H, Akagi-Kurashige Y, Hata M, Takahashi A, Tsujikawa A, Yoshimura N.
    Retina; 2017 Nov 27; 37(11):2062-2068. PubMed ID: 28590316
    [Abstract] [Full Text] [Related]

  • 17. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A, Gouliopoulos NS, Moschos MM, Theodossiadis P.
    BMC Ophthalmol; 2018 Oct 12; 18(1):267. PubMed ID: 30309335
    [Abstract] [Full Text] [Related]

  • 18. One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study.
    Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T, Murata T, Sakamoto T, Yoshida S, Sonoda KH, Ishibashi T.
    Ophthalmologica; 2017 Oct 12; 238(3):163-171. PubMed ID: 28697497
    [Abstract] [Full Text] [Related]

  • 19. Comparison of subfoveal choroidal structures in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Takahashi Y, Koizumi H, Hasegawa T, Izumi T, Maruko I, Sonoda S, Sakamoto T, Iida T.
    Jpn J Ophthalmol; 2018 Sep 12; 62(5):576-583. PubMed ID: 30069649
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
    Ophthalmologica; 2015 Sep 12; 234(1):33-9. PubMed ID: 26112059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.